Tapewire

Nasdaq · USD

TNDM

TANDEM DIABETES CARE INC

Export transactions ↓
Tapewire entity
4682
SEC CIK
0001438133
Parsed reports
672

Last 12 months

Inside the activity.

0 purchase rows · 2 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202602
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
May 15, 2025 Filed May 19, 2025 22:06 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionCommon Stock 304 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000089 · wk-form4_1747692404.xml · nonDerivative · entry 2

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,308

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
GrantCommon Stock 870 $19.30 $16,791.00
Disclosure

SEC source: 0001438133-25-000089 · wk-form4_1747692404.xml · nonDerivative · entry 1

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,004

F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 4,387 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · derivative · entry 13

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,774

Underlying: Common Stock · 4,387 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F9 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F12 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F12 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · derivative · entry 12

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,012

Underlying: Common Stock · 1,503 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F9 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 474 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · derivative · entry 11

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 474 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan.

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionRestricted Stock Unit · Derivative 162 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · derivative · entry 10

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 162 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 1,255 $22.70 $28,488.50
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 9

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,206

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 4,387 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 8

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,461

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 430 $22.70 $9,761.00
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 7

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,074

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 1,503 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 6

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,504

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 136 $22.70 $3,087.20
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 5

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,001

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 474 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 4

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,137

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Tax withholdingCommon Stock 47 $22.70 $1,066.90
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 3

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,663

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
Exercise / conversionCommon Stock 162 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 2

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,710

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Morrison SusanEVP & Chief Admin. Officer
GrantCommon Stock 1,359 $15.64 $21,254.76
Disclosure

SEC source: 0001438133-25-000088 · wk-form4_1747692391.xml · nonDerivative · entry 1

Morrison Susan · CIK 0001582970 · EVP & Chief Admin. Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,548

F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
Exercise / conversionRestricted Stock Unit · Derivative 3,589 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · derivative · entry 10

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,179

Underlying: Common Stock · 3,589 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
Exercise / conversionRestricted Stock Unit · Derivative 1,437 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · derivative · entry 9

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,748

Underlying: Common Stock · 1,437 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F7 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F8 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F8 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
Exercise / conversionRestricted Stock Unit · Derivative 596 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · derivative · entry 8

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 596 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 25, 2022 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F4 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F5 · derivative.exercise_date: RSU vest as to thiry-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to thiry-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
Tax withholdingCommon Stock 1,285 $22.70 $29,169.50
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 7

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,020

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
Exercise / conversionCommon Stock 3,589 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 6

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,305

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
Tax withholdingCommon Stock 515 $22.70 $11,690.50
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 5

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,716

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
Exercise / conversionCommon Stock 1,437 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 4

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,231

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
Tax withholdingCommon Stock 214 $22.70 $4,857.80
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 3

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,794

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
Exercise / conversionCommon Stock 596 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 2

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,008

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Carpenter RickChief Technology Officer
GrantCommon Stock 1,020 $15.64 $15,952.80
Disclosure

SEC source: 0001438133-25-000086 · wk-form4_1747692365.xml · nonDerivative · entry 1

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,412

F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionRestricted Stock Unit · Derivative 23,929 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 13

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,858

Underlying: Common Stock · 23,929 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · security: Awarded on May 23, 2024 pursuant to the 2023 Plan.

F9 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F12 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F12 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2025, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionRestricted Stock Unit · Derivative 5,472 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 12

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,886

Underlying: Common Stock · 5,472 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · security: Awarded on May 25, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F9 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F10 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F10 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionRestricted Stock Unit · Derivative 2,236 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 11

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,236 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan.

F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F7 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F7 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2023, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionRestricted Stock Unit · Derivative 792 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · derivative · entry 10

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 792 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F4 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F5 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

F5 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 5/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 12,152 $22.70 $275,850.40
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 9

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,327

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 23,929 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 8

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,479

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 2,779 $22.70 $63,083.30
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 7

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,550

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 5,472 $22.70 $124,214.40
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 6

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 1,136 $22.70 $25,787.20
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 5

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,857

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 2,236 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 4

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,993

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Tax withholdingCommon Stock 403 $22.70 $9,148.10
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 3

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,757

F2 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
Exercise / conversionCommon Stock 792 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 2

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,160

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
May 15, 2025 Filed May 19, 2025 22:06 UTC
Sheridan John FDirector · PRESIDENT & CEO
GrantCommon Stock 1,359 $15.64 $21,254.76
Disclosure

SEC source: 0001438133-25-000085 · wk-form4_1747692353.xml · nonDerivative · entry 1

Sheridan John F · CIK 0001365369 · Director · PRESIDENT & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,368

F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
May 15, 2025 Filed May 19, 2025 22:05 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
GrantCommon Stock 171 $19.30 $3,300.30
Disclosure

SEC source: 0001438133-25-000084 · wk-form4_1747692340.xml · nonDerivative · entry 1

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,709

F1 · acquired: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (ESPP), for the ESPP purchase period of November 18, 2024, through May 15, 2025. This transaction is also exempt under Rule 16b-3(c).

Read SEC document
March 17, 2025 Filed Mar 19, 2025 20:12 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionRestricted Stock Unit · Derivative 7,415 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000046 · wk-form4_1742415145.xml · derivative · entry 3

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,902

Underlying: Common Stock · 7,415 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on December 15, 2023 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

F4 · derivative.exercise_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 12/15/2024, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.

Read SEC document
March 17, 2025 Filed Mar 19, 2025 20:12 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Tax withholdingCommon Stock 2,739 $19.17 $52,506.63
Disclosure

SEC source: 0001438133-25-000046 · wk-form4_1742415145.xml · nonDerivative · entry 2

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,134

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
March 17, 2025 Filed Mar 19, 2025 20:12 UTC
Novara Mark DavidEVP & CHIEF COMMERCIAL OFFICER
Exercise / conversionCommon Stock 7,415 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000046 · wk-form4_1742415145.xml · nonDerivative · entry 1

Novara Mark David · CIK 0002000342 · EVP & CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 17, 2025 Filed Mar 19, 2025 20:12 UTC
Carpenter RickChief Technology Officer
Exercise / conversionRestricted Stock Unit · Derivative 406 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000045 · wk-form4_1742415136.xml · derivative · entry 3

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,218

Underlying: Common Stock · 406 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Awarded on December 15, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.

F4 · derivative.exercise_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 12/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

F4 · derivative.expiration_date: RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 12/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter.

Read SEC document
March 17, 2025 Filed Mar 19, 2025 20:12 UTC
Carpenter RickChief Technology Officer
Tax withholdingCommon Stock 146 $19.17 $2,798.82
Disclosure

SEC source: 0001438133-25-000045 · wk-form4_1742415136.xml · nonDerivative · entry 2

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,392

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of restricted stock units (RSU). No shares were sold.

Read SEC document
March 17, 2025 Filed Mar 19, 2025 20:12 UTC
Carpenter RickChief Technology Officer
Exercise / conversionCommon Stock 406 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000045 · wk-form4_1742415136.xml · nonDerivative · entry 1

Carpenter Rick · CIK 0001513889 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,538

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 22:06 UTC
Kyrillos Jean-ClaudeEVP & Chief Operating Officer
PurchaseCommon Stock 10,538 $18.12 $190,966.47
Disclosure

SEC source: 0001438133-25-000042 · wk-form4_1741730755.xml · nonDerivative · entry 1

Kyrillos Jean-Claude · CIK 0001804186 · EVP & Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,538

F1 · price: This transaction was executed in multiple trades at prices ranging from $18.115 to $18.13 per share. The reported price reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionPerformance Stock Unit · Derivative 5,523 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · derivative · entry 7

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,523 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · security: Awarded on May 25, 2022 pursuant to the 2013 Plan.

F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F4 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F4 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionPerformance Stock Unit · Derivative 1,380 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · derivative · entry 6

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,380 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · security: Awarded on May 18, 2021 pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the 2013 Plan).

F4 · derivative.exercise_price: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F4 · derivative.exercise_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

F4 · derivative.expiration_date: Each PSU represents a contingent right to receive one share of the Company common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the Measurement Date). The number of shares issued may range from 0% to 200% of the base grant amount, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Tax withholdingCommon Stock 3,009 $33.34 $100,320.06
Disclosure

SEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · nonDerivative · entry 4

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,023

F1 · kind: Shares withheld by Tandem Diabetes Care, Inc. (the Company) to satisfy tax withholding requirements on vesting of performance stock units (PSU). No shares were sold.

Read SEC document
February 25, 2025 Filed Feb 27, 2025 22:15 UTC
Gasser Elizabeth AnneEVP, Chief Strategy Officer
Exercise / conversionCommon Stock 5,523 $0.00 $0.00
Disclosure

SEC source: 0001438133-25-000038 · wk-form4_1740694524.xml · nonDerivative · entry 3

Gasser Elizabeth Anne · CIK 0001866283 · EVP, Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,032

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.